NCT06889610View on ClinicalTrials.gov

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.

NANot yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 28, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

May 1, 2028

Conditions
Triple Negative Breast Cancer MetastaticMelanoma Metastatic
Interventions
DEVICE

MTT(Multimodal Tumor Thermal Therapy System)- Triple-Negative Breast Cancer

MTT combined with Pucotenlimab, Sacituzumab Govitecan, Eribulin, and Gemcitabine

DEVICE

MTT(Multimodal Tumor Thermal Therapy System)- Melanoma

MTT combined with Pucotenlimab, with other specific drugs determined based on first-line treatment regimen and classification.

Trial Locations (1)

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER